Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments.
Company profile
Ticker
BSX
Exchange
Website
CEO
Michael Mahoney
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Acotec Scientific Holdings Limited • Acurate Industria e Comercio Ltda. • American Medical Systems Europe B.V. • Apollo Endosurgery Australia Pty Ltd • Apollo Endosurgery Brasil Aparelhos Cirurgicos Ltda. • Apollo Endosurgery Canada Ltd. • Apollo Endosurgery Costa Rica, S.R.L. • Apollo Endosurgery International, LLC • Apollo Endosurgery UK Ltd • Apollo Endosurgery US, Inc. ...
IRS number
42695240
BSX stock data
Analyst ratings and price targets
Latest filings (excl ownership)
10-Q
2024 Q2
Quarterly report
1 Aug 24
8-K
Boston Scientific Elects David Habiger to Board of Directors
30 Jul 24
8-K
Boston Scientific Announces Results for Second Quarter 2024
24 Jul 24
SD
Conflict minerals disclosure
23 May 24
8-K
Boston Scientific Elects Dr. Cheryl Pegus to Board of Directors
10 May 24
8-K
Amendments to Articles of Incorporation or Bylaws
6 May 24
10-Q
2024 Q1
Quarterly report
1 May 24
DEFA14A
Additional proxy soliciting materials
29 Apr 24
8-K
Boston Scientific Announces Results for First Quarter 2024
24 Apr 24
8-K
Other Events
4 Apr 24
Transcripts
BSX
Earnings call transcript
2024 Q2
24 Jul 24
BSX
Earnings call transcript
2024 Q1
24 Apr 24
BSX
Earnings call transcript
2023 Q4
31 Jan 24
BSX
Earnings call transcript
2023 Q3
26 Oct 23
BSX
Earnings call transcript
2023 Q2
27 Jul 23
BSX
Earnings call transcript
2023 Q2
27 Jul 23
BSX
Earnings call transcript
2023 Q1
26 Apr 23
BSX
Earnings call transcript
2022 Q4
1 Feb 23
BSX
Earnings call transcript
2022 Q3
26 Oct 22
BSX
Earnings call transcript
2022 Q2
27 Jul 22
Latest ownership filings
4
Michael F Mahoney
8 Oct 24
4
Joseph Michael Fitzgerald
8 Oct 24
144
Notice of proposed sale of securities
7 Oct 24
144
Notice of proposed sale of securities
7 Oct 24
4
Wendy Carruthers
2 Oct 24
144
Notice of proposed sale of securities
1 Oct 24
4
Michael F Mahoney
6 Sep 24
144
Notice of proposed sale of securities
5 Sep 24
4
Wendy Carruthers
3 Sep 24
4
Michael F Mahoney
3 Sep 24
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2024
89.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1287 |
Opened positions | 195 |
Closed positions | 82 |
Increased positions | 523 |
Reduced positions | 394 |
13F shares | Current |
---|---|
Total value | 95.95 tn |
Total shares | 1.32 bn |
Total puts | 8.23 mm |
Total calls | 8.09 mm |
Total put/call ratio | 1.0 |
Largest owners | Shares | Value |
---|---|---|
FMR | 141.46 mm | $10.89 tn |
Vanguard | 129.87 mm | $10.00 tn |
BLK BlackRock | 126.42 mm | $9.74 tn |
STT State Street | 61.46 mm | $4.73 tn |
Primecap Management | 37.96 mm | $2.92 tn |
Wellington Management | 32.10 mm | $2.47 tn |
Massachusetts Financial Services | 31.79 mm | $2.45 tn |
Geode Capital Management | 29.10 mm | $2.23 tn |
BAC Bank of America | 27.43 mm | $2.11 tn |
JPM JPMorgan Chase & Co. | 26.56 mm | $2.05 tn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
7 Oct 24 | Michael F Mahoney | Common Stock | Sell | Dispose S | No | Yes | 84.9416 | 82,085 | 6.97 mm | 1,572,096 |
7 Oct 24 | Michael F Mahoney | Common Stock | Sell | Dispose S | No | Yes | 84.3127 | 80,692 | 6.80 mm | 1,654,181 |
7 Oct 24 | Michael F Mahoney | Common Stock | Option exercise | Acquire M | No | Yes | 16.31 | 55,675 | 908.06 k | 1,734,873 |
7 Oct 24 | Michael F Mahoney | Common Stock | Option exercise | Acquire M | No | Yes | 17.26 | 56,211 | 970.20 k | 1,679,198 |
7 Oct 24 | Michael F Mahoney | Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 16.31 | 55,675 | 908.06 k | 55,676 |
7 Oct 24 | Michael F Mahoney | Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 17.26 | 56,211 | 970.20 k | 224,846 |
7 Oct 24 | Joseph Michael Fitzgerald | Common Stock | Sell | Dispose S | No | Yes | 85.0007 | 132,527 | 11.26 mm | 160,467 |
7 Oct 24 | Joseph Michael Fitzgerald | Common Stock | Option exercise | Acquire M | No | Yes | 24.98 | 57,618 | 1.44 mm | 292,994 |
7 Oct 24 | Joseph Michael Fitzgerald | Common Stock | Option exercise | Acquire M | No | Yes | 17.26 | 59,021 | 1.02 mm | 235,376 |
7 Oct 24 | Joseph Michael Fitzgerald | Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 24.98 | 57,618 | 1.44 mm | 0 |
News
Boston Scientific's Options Frenzy: What You Need to Know
21 Oct 24
TD Cowen Maintains Buy on Boston Scientific, Raises Price Target to $100
21 Oct 24
Critical Insights From Boston Scientific Analyst Ratings: What You Need To Know
21 Oct 24
Canaccord Genuity Maintains Buy on Boston Scientific, Raises Price Target to $98
21 Oct 24
Boston Scientific Launches Next Generation Of Cardiac Mapping For The FARAPULSE Pulsed Field Ablation System
18 Oct 24
Press releases
Boston Scientific Launches Next Generation of Cardiac Mapping for the FARAPULSE™ Pulsed Field Ablation System
18 Oct 24
Boston Scientific Receives Japanese Regulatory Approval for the FARAPULSE™ Pulsed Field Ablation System
27 Sep 24
Boston Scientific Closes Acquisition of Silk Road Medical, Inc.
17 Sep 24
Boston Scientific Receives FDA Approval for Expanded Indication of INGEVITY™+ Pacing Leads to Include Conduction System Pacing of the Left Bundle Branch Area
17 Sep 24
A New Standard in Drug Testing: Intelligent Bio (NASDAQ: INBS) Delivering Cost-Efficiency, Rapid Results, and Employee Dignity more stocks inside…
28 Aug 24